Financial Data and Key Metrics Changes - Revenue and other income amounted to EUR 9 million, including EUR 2.8 million from licensing and collaboration agreements and EUR 6.2 million in governmental funding for research expenditures [55] - Operating expenses were EUR 63 million, with R&D expenses decreasing by 16% year-over-year to EUR 43.6 million, reflecting study maturity and reduced indirect R&D expenses [56] - Cash position at the end of 2025 was EUR 44.8 million, providing funding visibility until the end of the third quarter of 2026 [57] Business Line Data and Key Metrics Changes - Focus on three priority programs: lacutamab, IPH4502, and monalizumab, with significant progress reported in each [6][11] - Lacutamab received FDA clearance for the TELLOMAK 3 phase III trial, expected to initiate in the second half of 2026 [8][18] - IPH4502 is advancing rapidly with early signs of antitumor activity in heavily pretreated patients, particularly in urothelial cancer [9][40] Market Data and Key Metrics Changes - Estimated 300 incident patients per year in Sézary syndrome in the U.S., with a prevalence of around 1,000 patients, primarily treated in specialized academic centers [22] - Mycosis fungoides represents a larger opportunity with approximately 3,000 incident patients per year and a prevalence of around 12,000 patients in the U.S. [25] - Mogamulizumab generated approximately $300 million in annual sales in 2025, projected to reach $350 million in 2026 [25] Company Strategy and Development Direction - Company aims to deliver high-value differentiated therapies for patients with significant unmet medical needs, focusing on late-stage development of its pipeline [4][5] - Strategic focus on three high-value clinical assets allows for concentrated resource allocation to generate clinical impact and long-term value [6] - Plans to leverage internal expertise and platform capabilities to advance the next generation of antibody-drug conjugates (ADCs) [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of IPH4502 to address significant unmet needs in the post-PADCEV setting and expand into other tumor types [60] - The company is negotiating non-dilutive financing options to support the initiation of the TELLOMAK 3 study for lacutamab [61] - Upcoming data readouts for monalizumab and IPH4502 are expected to create inflection points for the company [110] Other Important Information - The partnership with AstraZeneca for monalizumab includes potential milestones of up to $1.275 billion, with $450 million already received [52] - The MATISSE phase II trial for IPH5201 is ongoing, with results from an interim analysis expected to be presented at the AACR Annual Meeting [51] Q&A Session Summary Question: Updates on IPH4502 program and competitive positioning - Management highlighted strong interest in IPH4502 and its differentiation as a topo 1 ADC, focusing on the post-PADCEV setting [66] Question: MATISSE interim data presentation at AACR - The interim analysis will provide insights into the trial's efficacy and the potential path forward for lung cancer development [70] Question: Collaboration revenue from monalizumab program - Management clarified that revenue from the old agreement has dropped as the project is now fully under AstraZeneca's control [72] Question: Updates on lacutamab partnership discussions - Management is evaluating options for financing and partnership structures to maximize shareholder value [90] Question: Sales infrastructure for lacutamab - If pursued independently, a small sales team of around 20 people would be needed, focusing on specialized academic centers [105]

Financial Data and Key Metrics Changes - Revenue and other income amounted to EUR 9 million, including EUR 2.8 million from licensing and collaboration agreements and EUR 6.2 million in governmental funding for research expenditures [33] - Operating expenses were EUR 63 million, with R&D expenses decreasing by 16% year-over-year to EUR 43.6 million, reflecting study maturity and reduced indirect R&D expenses [33] - Cash position at the end of 2025 was EUR 44.8 million, providing funding visibility until the end of the third quarter of 2026 [33] Business Line Data and Key Metrics Changes - The company is prioritizing three high-value clinical assets: IPH4502, lacutamab, and monalizumab, focusing resources on these areas to generate clinical impact and long-term value [5][6] - Lacutamab has received FDA clearance to proceed with the TELLOMAK 3 phase III trial, expected to initiate in the second half of 2026 [7][10] - IPH4502 is progressing rapidly with early signs of antitumor activity in heavily pretreated patients, particularly in urothelial cancer [7][8] Market Data and Key Metrics Changes - The market for lacutamab in CTCL is concentrated, with approximately 300 incident patients per year in Sézary syndrome and around 1,000 patients in total, primarily treated in specialized academic centers [14][15] - Mycosis fungoides represents a larger opportunity with approximately 3,000 incident patients per year and a prevalence of around 12,000 patients in the U.S. [15] - Mogamulizumab generated approximately $300 million in annual sales in 2025, projected to reach $350 million in 2026, highlighting the market potential for lacutamab [15] Company Strategy and Development Direction - The company aims to advance its pipeline of differentiated therapies for significant unmet medical needs, focusing on late-stage development and key clinical and regulatory milestones [4][5] - A streamlined organization supports efficient decision-making and disciplined capital allocation, with a redundancy plan expected to be completed by the end of April [5] - The strategic focus on high-value clinical assets allows the company to concentrate resources effectively [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the progress of IPH4502 and its potential to address unmet needs in the post-PADCEV setting, with a focus on expanding into earlier lines of therapy [36] - The company is negotiating non-dilutive financing options to support the initiation of the TELLOMAK 3 study for lacutamab [36] - The upcoming data readouts for monalizumab and IPH4502 are expected to create significant inflection points for the company [36][37] Other Important Information - The partnership with AstraZeneca for monalizumab and IPH5201 includes potential milestone payments of up to $1.275 billion and $885 million, respectively [31][32] - The MATISSE phase II trial for IPH5201 is ongoing, with results from an interim analysis expected to be presented at the AACR Annual Meeting [30][44] Q&A Session Summary Question: Can you provide specifics regarding the IPH4502 program and its competitive positioning? - Management highlighted strong interest in IPH4502 and its differentiation as a Topo 1 ADC, focusing on the post-PADCEV setting [40][41] Question: What can be expected from the MATISSE interim data presentation at AACR? - The interim analysis will provide insights into the trial's efficacy and the potential path forward for development in lung cancer [44] Question: What is the status of collaboration revenue from the monalizumab program? - Revenue from the collaboration has dropped as the project is now fully under AstraZeneca's control, with future development dependent on upcoming results [46] Question: How does CD39 fit in relation to CD73 in the context of the MATISSE trial? - CD39 is upstream in the adenosine pathway, and blocking it can enhance immune stimulation, making it a valuable target in combination with chemotherapy [55][56] Question: What sales infrastructure is the company considering for lacutamab? - The company is evaluating whether to build its own sales team or partner with a BD partner, estimating a small commercial infrastructure would suffice for the CTCL market [72]

Financial Data and Key Metrics Changes - Revenue and other income for 2025 amounted to EUR 9 million, including EUR 2.8 million from licensing and collaboration agreements and EUR 6.2 million in governmental funding for research expenditures [33] - Operating expenses were EUR 63 million, with R&D expenses at EUR 43.6 million, a decrease of 16% year-over-year, reflecting study maturity and reduced indirect R&D expenses [33] - Cash position at the end of 2025 was EUR 44.8 million, providing funding visibility until the end of Q3 2026 [33] Business Line Data and Key Metrics Changes - The company is focusing on three high-value clinical assets: IPH4502, lacutamab, and monalizumab, with significant progress reported in their development [5][6] - IPH4502 is showing preliminary antitumor activity in heavily pretreated patients, particularly in urothelial cancer [7][23] - Lacutamab has received FDA clearance for the TELLOMAK 3 phase III trial, expected to initiate in the second half of 2026 [9][10] Market Data and Key Metrics Changes - In the U.S., there are approximately 300 incident patients per year in Sézary syndrome, with a prevalence of around 1,000 patients, primarily treated in specialized academic centers [14][15] - Mycosis fungoides represents a larger opportunity with approximately 3,000 incident patients per year and a prevalence of around 12,000 patients in the U.S. [16] Company Strategy and Development Direction - The company aims to deliver high-value differentiated therapies for significant unmet medical needs, focusing on late-stage development of its pipeline [5][6] - A strategic focus on IPH4502, lacutamab, and monalizumab allows for concentrated resource allocation to generate clinical impact and long-term value [6] - The company is exploring potential pharma partnerships and royalty-based structures to support late-stage development while preserving shareholder value [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the progress of their clinical programs and the potential for multiple catalysts in the near and medium term [8][36] - The company is negotiating non-dilutive financing options to support the initiation of the TELLOMAK 3 study for lacutamab [36] Other Important Information - The partnership with AstraZeneca for monalizumab and IPH5201 includes significant milestone payments, with potential royalties on sales [31][32] - The company has streamlined its organization to ensure efficient decision-making and disciplined capital allocation [6] Q&A Session Summary Question: Can you provide specifics regarding the IPH4502 program and its competitive positioning? - Management highlighted strong interest in IPH4502 and its differentiation as a Topo 1 ADC, focusing on the post-PADCEV setting [39][40] Question: What can be expected from the MATISSE interim data presentation at AACR? - The interim analysis will provide insights into the trial's efficacy and the potential path forward for development in lung cancer [42][44] Question: How is the collaboration revenue from the monalizumab program expected to evolve? - Future development will depend on upcoming results from the PACIFIC-9 trial, with current revenue reflecting the transition to AstraZeneca's control [45] Question: What updates can be shared regarding lacutamab's partnership discussions? - The company is evaluating options for financing and partnerships to bring lacutamab to market efficiently [58][60] Question: What kind of sales infrastructure is being considered for lacutamab? - If pursued independently, a small sales team of around 20 people would be sufficient due to the concentrated treatment landscape [70][71]

Core Points - NextCure, Inc. has entered into definitive agreements for a private placement of 2,523,477 shares of common stock at a price of $8.52 per share, expected to close on or about November 13, 2025 [1][3] - The gross proceeds from the offering are anticipated to be approximately $21.5 million, which will extend the company's cash runway into the first half of 2027 [3] - The net proceeds will be used for general working capital needs and to support proof of concept data readouts for two antibody drug conjugate programs, SIM0505 and LNCB74 [3][6] Company Overview - NextCure is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer patients who do not respond to existing treatments [6] - The company specializes in targeted therapies, including antibody-drug conjugates, leveraging its expertise in biological pathways and biomarkers [6]

Core Insights - IDEAYA Biosciences announced that results from a global Phase 2 study of neoadjuvant darovasertib in primary uveal melanoma will be presented at the 2025 ESMO meeting in Berlin [1][2] - The presentation will focus on the effects of darovasertib across plaque brachytherapy and enucleation cohorts, highlighting its potential impact on disease management [2][3] - The company has initiated a randomized Phase 3 neoadjuvant registrational trial (OptimUM-10) for darovasertib in primary uveal melanoma [6] Company Overview - IDEAYA Biosciences is a precision medicine oncology company focused on developing transformative therapies for cancer [3] - The company integrates drug discovery, structural biology, and bioinformatics to create targeted therapies for specific patient populations [3] - IDEAYA has a robust pipeline that includes therapies based on synthetic lethality and antibody-drug conjugates [3] Clinical Study Details - The upcoming presentation will include data from over 90 patients in both plaque brachytherapy and enucleation-eligible cohorts [6] - Darovasertib has received U.S. FDA Breakthrough Therapy Designation for neoadjuvant use in uveal melanoma patients requiring enucleation [6]

Core Viewpoint - Zymeworks Inc. is advancing its clinical-stage pipeline with the presentation of new preclinical data for ZW1528, a bispecific molecule targeting IL-4Rα and IL-33, aimed at treating respiratory inflammation, particularly chronic obstructive pulmonary disease (COPD) [1][2]. Group 1: Product Development - ZW1528 demonstrates high affinity binding to IL-4Rα and IL-33, effectively blocking IL-4, IL-13, and IL-33 signaling pathways, which are critical in respiratory inflammation [5][6]. - The bispecific design of ZW1528 shows promising manufacturability and stability, supporting high dosing concentrations and subcutaneous administration [5][7]. - Zymeworks is also developing ZW1572, another bispecific inhibitor targeting IL-4Rα and IL-31 for atopic dermatitis, as part of its expanding IL-4Rα program portfolio [3][5]. Group 2: Preclinical Data and Findings - Preclinical data presented at the ATS conference indicate that ZW1528 can suppress both Type 2 and non-Type 2 immune responses in primary human immune cells from COPD patients [6][7]. - In vivo studies in murine models of lung inflammation show efficacy for ZW1528, with extended pharmacokinetics observed in rodent and non-human primate models [6][7]. - The bispecific antibody's blockade of cytokine-driven activation in human epithelial cells is superior to that achieved with monoclonal antibodies targeting either IL-4Rα or IL-33 [7]. Group 3: Company Overview - Zymeworks is a global biotechnology company focused on developing multifunctional biotherapeutics for difficult-to-treat conditions, including cancer and autoimmune diseases [8]. - The company has a robust pipeline of product candidates and has entered into strategic partnerships to enhance its therapeutic platforms [8].

Financial Data and Key Metrics Changes - Total revenues for Q2 2020 were $278 million, driven by record product sales, with a year-to-date total of $513 million [21][5] - Product sales from oncology franchises totaled $240 million, reflecting a 51% increase from the previous year [22] - R&D expenses increased to $198 million in Q2 and $393 million for the first half of 2020, indicating a focus on pipeline investment [24] Business Line Data and Key Metrics Changes - ADCETRIS net sales were $168 million in Q2, with a full-year guidance maintained at $675 million to $700 million [6][25] - PADCEV net sales in the U.S. were $57 million in Q2, a 66% increase from Q1, with full-year guidance set at $215 million to $235 million [7][25] - TUKYSA generated $16 million in revenue in its first partial quarter post-launch [10] Market Data and Key Metrics Changes - The company reported strong adoption of PADCEV for metastatic urothelial cancer, with ongoing trials to expand its use [8][9] - TUKYSA is being positioned in the market for HER2 positive breast cancer, with approvals in multiple countries [10][11] Company Strategy and Development Direction - The company aims to expand the indications for its commercial brands and is advancing over a dozen early-stage assets in clinical and preclinical development [14] - A virtual R&D day is planned to provide more details on the pipeline and commitment to first-in-class therapies [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory despite challenges posed by the COVID-19 pandemic [5] - Positive feedback from KOLs on clinical data supports the potential for accelerated approvals in various indications [13][90] Other Important Information - The company ended Q2 with $896 million in cash and investments, bolstered by the sale of Immunomedics shares [24] - The company is refining its guidance for R&D expenses to a range of $820 million to $870 million for 2020 [25] Q&A Session Summary Question: Insights on TUKYSA's initial launch - Management noted it is early in the launch but is pleased with the awareness and uptake in both academic and community settings [41][42] Question: Factors affecting PADCEV's guidance - Management indicated that while the initial uptake has been strong, growth rates may slow as the launch progresses, with guidance reflecting a 35% to 55% growth rate in the second half [44][47] Question: Gating factors for BLA filing for TV - Management is actively working towards a BLA submission and is encouraged by the positive data from the pivotal trial [51][54] Question: Initial launch feedback for TUKYSA - There is significant enthusiasm among doctors regarding TUKYSA, and it is being used in both patients with and without brain metastases [58][61] Question: Details on the INNO2VATE trial - The trial is focused on evaluating the role of tisotumab vedotin as a single agent or in combination with other therapies for cervical cancer [67] Question: PADCEV usage in frontline settings - Management confirmed ongoing trials to evaluate PADCEV in combination with KEYTRUDA in frontline metastatic disease [75][78]

Core Viewpoint - Zymeworks Inc. has appointed Dr. Sabeen Mekan as Senior Vice President of Clinical Development, enhancing its leadership team to advance its clinical-stage oncology portfolio and diversify into autoimmune and inflammatory diseases [1][2]. Company Overview - Zymeworks Inc. is a clinical-stage biotechnology company focused on developing novel biotherapeutics for difficult-to-treat diseases, including cancer, inflammation, and autoimmune diseases [1][4]. - The company utilizes proprietary technologies to engineer and develop differentiated antibody-based therapeutic candidates, including zanidatamab, a HER2-targeted bispecific antibody [4][5]. Leadership Changes - Dr. Sabeen Mekan, with 18 years of experience in hematology and oncology, will play a crucial role in formulating the clinical development strategy for Zymeworks' oncology portfolio [2][3]. - Dr. Jeff Smith continues as Executive Vice President & Chief Medical Officer, focusing on R&D in autoimmune and inflammatory diseases [1][2]. - Barbara Schaeffler has been promoted to Senior Vice President, Clinical Development Operations, reporting to Dr. Smith [1]. Clinical Development Focus - The expanded clinical development team aims to enhance the focus on progressing Zymeworks' clinical-stage solid tumor portfolio while diversifying into autoimmune and inflammatory diseases [2]. - Dr. Mekan expressed commitment to addressing unmet needs in various cancer types through next-generation antibody-drug conjugates and multispecific antibody therapeutics [2][3]. Pipeline and Regulatory Progress - Zymeworks has received FDA accelerated approval for Ziihera® (zanidatamab-hrii) for treating adults with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer [4]. - The company is advancing a robust pipeline, with Phase 1 studies for ZW171 and ZW191 actively recruiting and an investigational new drug application for ZW251 planned for mid-2025 [5].